The in vivo CRO market involves contract research organizations that provide drug discovery and development services using live animal models. In vivo CROs help accelerate the drug development process by conducting preclinical studies, PK/PD studies, safety/toxicology testing, and regulatory support. Their animal testing services help evaluate a drug's efficacy, side effects, dosage optimization, and metabolic effects prior to human clinical trials. This reduces risks and saves significant costs compared to conducting preclinical research in-house.
The Global In vivo CRO Market is estimated to be valued at US$ 4.70 billion in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the in vivo CRO market are IQVIA Inc., Crown Bioscience, Taconic Biosciences, Inc., PsychoGenics Inc., Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc, Labcorp Drug Development, Parexel International Corporation, SMO Clinical Research (I) Pvt Ltd., WuXi AppTec, ICON plc, and Syneos Health.
In Vivo CRO Market Demand drug development activities and stringent regulations have increased the demand for specialized preclinical CRO services. Biopharma companies are actively outsourcing in vivo testing to CROs to reduce costs and focus on their core drug development competencies.
Major CROs are expanding globally through acquisitions and partnerships to cater to the growing demand from global biopharma companies and strengthen their service portfolios. Their in vivo testing facilities across regions allow biopharmas to conduct preclinical studies closer to their headquarters.
Market Key Trends
One of the key trends in the in vivo CRO market is the rise of customized preclinical services. CROs are developing specialized models and services tailored to the unique needs of new drug modalities like cell and gene therapies, biologics, and vaccines. They also provide project management and analytical services to help sponsors with data analysis and regulatory submissions. This holistic service approach aids faster translation of preclinical research insights into clinical development decisions.
Porter’s Analysis
Threat of new entrants: Moderate barriers to enter the market such as need for experienced professionals, high capital requirements for infrastructure and technologies
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternatives and competition between CROs
Bargaining power of suppliers: Suppliers have low bargaining power due to availability of alternative suppliers for clinical trial support services
Threat of new substitutes: Low threat as there are limited substitutes for CRO services which conduct preclinical and clinical trials for bringing new drug to market
Competitive rivalry: High competition among existing CROs to gain more market share as competition intensifies with more number of players entering the market
The geographical region where the in vivo CRO market is concentrated in terms of value is North America. North America accounts for the largest share of the global in vivo CRO market owing to factors such as presence of large pharmaceutical companies conducting clinical trials, stringent regulations for drug development, and availability of public and private funding for research.
The fastest growing region for the in vivo CRO market is Asia Pacific. The Asia Pacific region is expected to witness the highest CAGR during the forecast period due to increasing outsourcing of clinical trials to CROs by pharmaceutical companies, growing biopharmaceutical industry and medical tourism, large patient population and low cost of clinical trials, and favorable government policies supporting clinical research in several Asian countries. Countries such as China and India provide opportunities for cost savings which is attracting pharmaceutical companies to conduct clinical trials in Asia Pacific region.
Get This Report in Japanese Language:
Get This Report in Korean Language:
Explore More Related Article On- Antidepressant Market
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
